Description

What Is Vyvanse Used For? ADHD, Binge Eating Disorder, and Off-Label Uses Explained in 2026

What Is Vyvanse Used For?

Vyvanse is used for two TGA-approved conditions in Australia: Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 and older, and moderate-to-severe binge eating disorder (BED) in adults. It is also used off-label for treatment-resistant depression and narcolepsy under specialist guidance. In all of these uses, Vyvanse works by increasing dopamine and norepinephrine availability in the brain through its unique prodrug conversion mechanism.

---

Why This Matters

The reason “what is Vyvanse used for” is one of the most searched questions about this medication is that many people encounter it in one context — usually ADHD — and then discover it has other approved uses they weren’t aware of. Others have been prescribed it and want to understand whether it’s the right tool for their specific situation. Getting a clear, complete answer matters because Vyvanse is a Schedule 8 controlled medicine in Australia: the decision to use it, and for what, carries real clinical and regulatory weight.

---

What You Need to Know First

Vyvanse (lisdexamfetamine dimesylate) is a central nervous system (CNS) stimulant and a prodrug — meaning it is completely pharmacologically inactive until your red blood cells convert it into active dextroamphetamine through enzymatic hydrolysis. This conversion process is what gives Vyvanse its smooth, extended action and lower misuse potential compared to traditional amphetamine formulations.

Originally FDA-approved in 2007 for ADHD in children aged 6 to 12, Vyvanse subsequently received approval for adults with ADHD in 2008, and became the first medication ever approved for binge eating disorder in January 2015. In Australia, the TGA has approved Vyvanse across both indications, with all six dose strengths (20 mg to 70 mg) confirmed through independent laboratory testing.

---

Quick Answer Overview

• Primary use 1: ADHD treatment in patients aged 6 and older

• Primary use 2: Moderate-to-severe binge eating disorder in adults

• Off-label use: Treatment-resistant depression and narcolepsy

• Not approved for: Weight loss or obesity treatment

• Mechanism: Dopamine and norepinephrine elevation via prodrug conversion

• Duration of effect: 10–14 hours depending on dose

• Australian status: Schedule 8 controlled medicine — requires specialist prescription

---

Use 1: ADHD — The Primary Indication

What It Treats in ADHD

ADHD is a neurodevelopmental disorder characterised by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with daily functioning. It presents in three subtypes: predominantly inattentive, predominantly hyperactive-impulsive, and combined type. Vyvanse addresses all three presentations by targeting the underlying neurochemical dysfunction — specifically, under-regulated dopamine and norepinephrine signalling in the prefrontal cortex and reward circuits.

Who It Is Approved For

In Australia, Vyvanse is TGA-approved for ADHD in:

• Children aged 6 and older — initiated and supervised by a specialist paediatrician

• Adolescents — continued under specialist oversight with regular review

• Adults — prescribed by a psychiatrist or other relevant specialist with Schedule 8 authority

Vyvanse has not been tested in children under 6 with ADHD and is not approved for that age group.

What Improves With Vyvanse for ADHD

Patients and clinicians consistently report improvements across several domains:

• Sustained attention: Ability to stay focused on tasks, conversations, and reading without frequent derailment

• Impulse control: Reduced interrupting, reactive decision-making, and risk-taking behaviour

• Task initiation: Lower internal resistance to starting tasks that require effort

• Working memory: Better ability to hold and manipulate information in the short term

• Hyperactivity: Decreased physical restlessness and mental over-activity

• Organisation and planning: Improved ability to structure tasks, manage time, and follow through

ADHD in Australia: What the Prescription Process Looks Like

In Australia, ADHD diagnosis and Vyvanse initiation requires a specialist — typically a psychiatrist, paediatrician, or neurologist — not a GP. Once initiated, some GPs can continue prescriptions under authority. The Schedule 8 classification means prescriptions are tracked through state-based monitoring systems, and supply is typically limited to one month at a time.

---

Use 2: Binge Eating Disorder — The Second Approved Indication

What Is Binge Eating Disorder?

Binge eating disorder is the most common eating disorder in adults, characterised by recurrent episodes of consuming large amounts of food rapidly, accompanied by a loss of control and significant psychological distress — but unlike bulimia, without compensatory purging behaviours. It is associated with serious physical health consequences including obesity, type 2 diabetes, and cardiovascular disease, as well as severe impacts on mental health, relationships, and quality of life.

Why Vyvanse Works for BED

Vyvanse became the world’s first medication specifically approved for binge eating disorderwhen the FDA granted approval in January 2015. The Australian TGA followed with its own approval for this indication.

The mechanism is believed to involve the same dopaminergic pathway that underlies ADHD treatment. Binge eating is in part driven by dysregulated reward circuitry — the brain’s dopamine response to food-related cues becomes compulsive and overriding. By normalising dopamine signalling, Vyvanse reduces the neurological urgency driving binge episodes, giving patients a window of control that the disorder typically removes.

In two Phase 3 clinical trials involving 724 adults with moderate-to-severe BED, patients treated with Vyvanse at 50 mg or 70 mg daily had significantly greater reductions in binge days per week compared to placebo — approximately 3.87 to 3.92 fewer binge days per week versus 2.26 to 2.51 for placebo.

Important Limitation: Not a Weight Loss Drug

This point cannot be overstated: Vyvanse is explicitly not approved for weight loss or the treatment of obesity. Its approval for BED is specifically for the reduction of binge eating episodes in adults with the diagnosed disorder — not for general appetite suppression or weight management. Prescribing Vyvanse for weight loss purposes is outside approved indications in Australia and the US.

---

Off-Label Uses of Vyvanse

Beyond its two approved indications, Vyvanse is used off-label in specific clinical contexts under specialist supervision:

Treatment-Resistant Depression

Vyvanse is used as an augmentation strategy in patients with major depressive disorder who have not responded adequately to first-line antidepressants. The dopaminergic mechanism addresses specific depression symptoms that serotonin-targeting antidepressants often don’t resolve — particularly fatigue, low motivation, cognitive sluggishness (sometimes called “brain fog”), and anhedonia (inability to experience pleasure). It is not a first-line antidepressant and is not TGA-approved for depression in Australia.

Narcolepsy

Vyvanse’s wake-promoting and alertness-enhancing effects — a direct product of norepinephrine elevation — make it useful in narcolepsy management, where excessive daytime sleepiness is the primary burden. Again, this is off-label use in Australia and requires specialist prescription.

---

What Vyvanse Is Not Used For

Understanding the boundaries of Vyvanse’s appropriate use is as important as knowing its indications:

• Not for weight loss: Despite appetite suppression being a known side effect, prescribing Vyvanse for this purpose is outside approved indications and clinically inappropriate

• Not for general cognitive enhancement: Vyvanse does not deliver superior cognitive performance in people without ADHD — it restores function in a dysregulated system, not supercharges a typical one

• Not for fatigue or shift work: While it produces wakefulness, this is not an approved or recommended use

• Not for children under 6: Safety and efficacy data is absent for this age group

• Not for BED in under 18s: The BED indication is adults only; the paediatric BED data does not exist

---

Vyvanse vs Other ADHD Medications: Which Conditions Are Treated?

Vyvanse’s dual ADHD/BED approval makes it the only stimulant medication in Australia with a formal eating disorder indication — a distinction that matters clinically when patients present with both conditions simultaneously, which is not uncommon given the significant overlap between ADHD and BED in the adult population.

---

Safety and Important Considerations for Australian Users

In Australia, Vyvanse requires a specialist prescription under the Schedule 8 controlled medicines framework. This means a GP alone cannot initiate Vyvanse — an authorised specialist (psychiatrist, paediatrician, or other relevant specialist) must make the diagnosis and write the initial prescription. Some states allow GPs to continue prescriptions under authority once treatment is established.

A specific safety note for BED patients: do not use Vyvanse as a substitute for eating disorder treatment. Clinical guidelines position it as one component of a comprehensive BED treatment plan, which should include psychological therapy such as cognitive behavioural therapy (CBT). Dieting is also explicitly cautioned against when initiating Vyvanse for BED — restrictive eating can trigger binge episodes that directly undermine the medication’s therapeutic purpose.

For all users: Vyvanse carries cardiovascular risks — elevated heart rate and blood pressure — that require monitoring. Patients with existing heart conditions, structural cardiac abnormalities, or hypertension should discuss these risks explicitly with their prescriber before starting Vyvanse at any dose.

---

Common Misconceptions About What Vyvanse Is Used For

Myth 1: “Vyvanse is just used to calm hyperactive kids down.”
This framing is two decades out of date and clinically inaccurate. Vyvanse is approved for all three ADHD presentations — including the predominantly inattentive type, which often presents without any hyperactivity at all. It is also approved and widely used in adults. The “calm kids down” narrative conflates ADHD with a behaviour problem rather than recognising it as a neurobiological condition affecting people across their entire lifespan.

Myth 2: “Vyvanse is prescribed for weight loss in Australia.”
It is not. The TGA approval is specifically for binge eating disorder — a psychiatric condition defined by compulsive eating episodes and loss of control — not for weight management or cosmetic purposes. Any prescriber offering Vyvanse for weight loss is operating outside approved indications, and patients should be aware of this distinction.

Myth 3: “If Vyvanse helps you focus, you must have ADHD.”
Stimulant medications improve certain aspects of focus and alertness in virtually everyone — with or without ADHD — via the same dopaminergic and noradrenergic mechanisms. A positive response to Vyvanse is not diagnostic of ADHD. The therapeutic benefit in ADHD specifically involves normalising a dysregulated neurochemical system, which is a meaningfully different experience from the stimulant effect seen in neurotypical users.

---

Buying Guide: What to Know Before Pursuing a Vyvanse Prescription in Australia

If you’re exploring Vyvanse as a treatment option, these are the practical realities:

1. You need a formal diagnosis first — ADHD or BED must be diagnosed by an appropriate specialist; self-diagnosis is not sufficient for a Schedule 8 prescription

2. Expect a thorough assessment — for ADHD in adults, the diagnostic process typically involves structured clinical interviews, symptom rating scales, and often a review of childhood history

3. Titration takes time — most patients start at 20–30 mg and increase gradually; finding the right dose takes weeks to months, not days

4. Budget for ongoing specialist reviews — the Schedule 8 framework requires periodic review appointments, not just initial prescription

5. It works best as part of a broader plan — clinical guidelines recommend Vyvanse as one component of ADHD management, alongside behavioural strategies, psychological support, and lifestyle adjustments; medication alone is rarely sufficient for optimal outcomes.

---

FAQ — People Also Ask

Can Vyvanse be used for anxiety in Australia?
No — Vyvanse is not approved for anxiety and is generally cautioned against in patients with anxiety disorders, as stimulants can worsen anxiety symptoms. If anxiety is co-occurring with ADHD, which is common, treatment sequencing and medication choice require careful specialist management. Some patients find their anxiety actually improves when ADHD is treated, because much of the anxiety was being driven by unmanaged ADHD symptoms.

Is Vyvanse used differently for adults versus children with ADHD?
The therapeutic purpose is identical — improved focus, impulse control, and attention. The clinical difference lies in dosing (weight-guided in children, symptom-guided in adults), prescribing authority (paediatrician for children, psychiatrist or relevant specialist for adults), and monitoring requirements (growth monitoring in children, cardiovascular monitoring at all ages).

Can Vyvanse be used long-term for ADHD?
Yes — ADHD is a chronic condition and long-term Vyvanse use is clinically supported and common. It requires ongoing specialist review in Australia under Schedule 8 regulations. Long-term use is associated with sustained improvement in ADHD symptoms without dramatic loss of efficacy, though dose adjustments may be needed over time.

Is Vyvanse used for autism in Australia?
Vyvanse is not TGA-approved for autism spectrum disorder. However, ADHD and autism frequently co-occur, and when both are present, the ADHD component can be treated with Vyvanse under the ADHD indication. This is a specialist decision requiring careful clinical assessment.

Does Vyvanse help with depression caused by ADHD?
Many patients with undiagnosed or undertreated ADHD experience secondary depression — low mood and self-worth arising from years of struggle with an unrecognised neurological difference. Vyvanse can improve this indirectly by treating the ADHD itself. Its off-label use in treatment-resistant depression is specifically for primary major depressive disorder that hasn’t responded to antidepressants — not as a general mood elevator.

Why isn’t Vyvanse approved for obesity if it suppresses appetite?
Appetite suppression is a side effect, not a therapeutic mechanism. The FDA and TGA have not reviewed or approved Vyvanse for obesity because the safety profile of long-term stimulant use specifically for weight management — as opposed to the treatment of a psychiatric disorder — has not been established for that indication. The clinical risks, including cardiovascular effects and dependence potential, are not considered justified for a non-psychiatric weight management purpose.

Can Vyvanse be used to treat ADHD and binge eating disorder at the same time?
Yes — this is one of the most clinically valuable aspects of Vyvanse’s dual approval. Given the significant overlap between ADHD and BED in adults, patients presenting with both conditions can be treated under a single medication. This requires specialist oversight and close monitoring, but avoids the complexity of managing two separate pharmacological approaches simultaneously.

---

Vyvanse is used for two conditions in Australia: ADHD across the lifespan and binge eating disorder in adults — with the same dopaminergic and noradrenergic mechanism driving improvements in both. It remains the only stimulant medication with dual ADHD and BED approval, which makes it uniquely valuable for the substantial patient population where both conditions co-exist.